CD19 chimeric antigen receptor T-cell therapy following autologous stem cell transplantation against relapsed or refractory Burkitt lymphoma/leukemia: A case report and literature review

Burkitt lymphoma or leukemia (BL) is a highly aggressive non-Hodgkin lymphoma. Older age (over 60 years old) and the presence of high-risk factors (such as abdominal mass, high levels of the serum lactic dehydrogenase, Ann Arbor stage II-IV and so on) usually predict a poorer outcome. Chimeric antig...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Mingyu, Gao, Lei, Wang, Tao, Yu, Jiechen, Gui, Jiaping, Yang, Jianmin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9639856/
https://www.ncbi.nlm.nih.gov/pubmed/36353549
http://dx.doi.org/10.3389/fonc.2022.932254
_version_ 1784825727935315968
author Ye, Mingyu
Gao, Lei
Wang, Tao
Yu, Jiechen
Gui, Jiaping
Yang, Jianmin
author_facet Ye, Mingyu
Gao, Lei
Wang, Tao
Yu, Jiechen
Gui, Jiaping
Yang, Jianmin
author_sort Ye, Mingyu
collection PubMed
description Burkitt lymphoma or leukemia (BL) is a highly aggressive non-Hodgkin lymphoma. Older age (over 60 years old) and the presence of high-risk factors (such as abdominal mass, high levels of the serum lactic dehydrogenase, Ann Arbor stage II-IV and so on) usually predict a poorer outcome. Chimeric antigen receptor T cells (CART) have achieved remarkable success in the treatment of B-cell leukemia and lymphoma. Here, for the first time, we report a 61-year-old, high-risk BL patient with autologous stem cell transplantation (ASCT) bridging therapy prior to CART as consolidation therapy. Our findings demonstrate that the combination of ASCT and CART for BL is safe and feasible.
format Online
Article
Text
id pubmed-9639856
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96398562022-11-08 CD19 chimeric antigen receptor T-cell therapy following autologous stem cell transplantation against relapsed or refractory Burkitt lymphoma/leukemia: A case report and literature review Ye, Mingyu Gao, Lei Wang, Tao Yu, Jiechen Gui, Jiaping Yang, Jianmin Front Oncol Oncology Burkitt lymphoma or leukemia (BL) is a highly aggressive non-Hodgkin lymphoma. Older age (over 60 years old) and the presence of high-risk factors (such as abdominal mass, high levels of the serum lactic dehydrogenase, Ann Arbor stage II-IV and so on) usually predict a poorer outcome. Chimeric antigen receptor T cells (CART) have achieved remarkable success in the treatment of B-cell leukemia and lymphoma. Here, for the first time, we report a 61-year-old, high-risk BL patient with autologous stem cell transplantation (ASCT) bridging therapy prior to CART as consolidation therapy. Our findings demonstrate that the combination of ASCT and CART for BL is safe and feasible. Frontiers Media S.A. 2022-10-24 /pmc/articles/PMC9639856/ /pubmed/36353549 http://dx.doi.org/10.3389/fonc.2022.932254 Text en Copyright © 2022 Ye, Gao, Wang, Yu, Gui and Yang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Ye, Mingyu
Gao, Lei
Wang, Tao
Yu, Jiechen
Gui, Jiaping
Yang, Jianmin
CD19 chimeric antigen receptor T-cell therapy following autologous stem cell transplantation against relapsed or refractory Burkitt lymphoma/leukemia: A case report and literature review
title CD19 chimeric antigen receptor T-cell therapy following autologous stem cell transplantation against relapsed or refractory Burkitt lymphoma/leukemia: A case report and literature review
title_full CD19 chimeric antigen receptor T-cell therapy following autologous stem cell transplantation against relapsed or refractory Burkitt lymphoma/leukemia: A case report and literature review
title_fullStr CD19 chimeric antigen receptor T-cell therapy following autologous stem cell transplantation against relapsed or refractory Burkitt lymphoma/leukemia: A case report and literature review
title_full_unstemmed CD19 chimeric antigen receptor T-cell therapy following autologous stem cell transplantation against relapsed or refractory Burkitt lymphoma/leukemia: A case report and literature review
title_short CD19 chimeric antigen receptor T-cell therapy following autologous stem cell transplantation against relapsed or refractory Burkitt lymphoma/leukemia: A case report and literature review
title_sort cd19 chimeric antigen receptor t-cell therapy following autologous stem cell transplantation against relapsed or refractory burkitt lymphoma/leukemia: a case report and literature review
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9639856/
https://www.ncbi.nlm.nih.gov/pubmed/36353549
http://dx.doi.org/10.3389/fonc.2022.932254
work_keys_str_mv AT yemingyu cd19chimericantigenreceptortcelltherapyfollowingautologousstemcelltransplantationagainstrelapsedorrefractoryburkittlymphomaleukemiaacasereportandliteraturereview
AT gaolei cd19chimericantigenreceptortcelltherapyfollowingautologousstemcelltransplantationagainstrelapsedorrefractoryburkittlymphomaleukemiaacasereportandliteraturereview
AT wangtao cd19chimericantigenreceptortcelltherapyfollowingautologousstemcelltransplantationagainstrelapsedorrefractoryburkittlymphomaleukemiaacasereportandliteraturereview
AT yujiechen cd19chimericantigenreceptortcelltherapyfollowingautologousstemcelltransplantationagainstrelapsedorrefractoryburkittlymphomaleukemiaacasereportandliteraturereview
AT guijiaping cd19chimericantigenreceptortcelltherapyfollowingautologousstemcelltransplantationagainstrelapsedorrefractoryburkittlymphomaleukemiaacasereportandliteraturereview
AT yangjianmin cd19chimericantigenreceptortcelltherapyfollowingautologousstemcelltransplantationagainstrelapsedorrefractoryburkittlymphomaleukemiaacasereportandliteraturereview

Ejemplares similares